Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

NCT01838850 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: CS8635 20/5/12.5mg and placebo
DRUG: Olmetec® Plus 20/12.5mg and placebo

Sponsor

Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company